No Data
No Data
Suzhou Basecare Medical Forecasts Up to 62% Rise in H1 Revenue
Suzhou Basecare Medical (HKG:2170) forecasts its revenue will rise 49% to 62% to between 127.3 million yuan and 138.4 million yuan in the six months ended June 30, from 85.5 million yuan in the year-
Beacon Medical Group - B (02170.HK): revenue increased by 49%-62% year-on-year in the first half of the year.
On July 12th, GlobeNewswire reported that Becon Medical-B (02170.HK) announced that during the period from January 1st to June 30th, 2024, the group's revenue was approximately 1.273-0.1384 billion yuan, a year-on-year increase of about 49%-62%. The announcement stated that the increase in revenue during this period was mainly due to (i) the group's acquisition of Singaporean BMX Holdco Pte. Ltd. and then combining its financial performance into the group's global sales performance. The group has built an extensive global sales network and has achieved international sales of domestically developed products while overseas performance continues to grow.
The Market Lifts Suzhou Basecare Medical Corporation Limited (HKG:2170) Shares 27% But It Can Do More
Suzhou Basecare Medical Corporation Limited (HKG:2170) shareholders would be excited to see that the share price has had a great month, posting a 27% gain and recovering from prior weakness. Unfort
BASECARE-B: ANNUAL REPORT 2023
Beacon Medical (2170.HK) achieved a 50% increase in both revenue and gross profit, with the heavyweight acquisition helping to create a Chinese version of Vitrolife.
Since Beijing first included 16 assisted reproduction projects in medical insurance in June last year, with the promotion of the National Medical Insurance Bureau, Guangxi, Inner Mongolia, Gansu, and other places have also followed suit and included some assisted reproduction projects in medical insurance, including oocyte retrieval, embryo culture, embryo transplantation, sperm selection, pre-implantation genetic diagnosis for monogenic diseases (PGT-M), pre-implantation genetic diagnosis for chromosomal disorders (PGT-SR), cell cryopreservation, etc. The overall reimbursement ratio of these projects is as high as 50%-70%, and some projects can even achieve second reimbursement.
BASECARE MEDICAL-B (02170. HK) Announces Annual Performance: Revenue and Gross Profit Growth of 48% and 53%, Completing Acquisition of BMX to Accelerate Globalization Layout
Basecare Medical-B (02170. HK) announced its annual performance. As of December 31, 2023, the group's revenue was RMB 208 million, a year-on-year increase of approximately 48%; The gross profit was RM
No Data